natgillin/translations-raw huggingface dataset:
Median time to onset of the first SRE was not reached in the zoledronic acid-treated arm at the end of the study and was significantly prolonged compared to placebo (p=0.007). 
zdravljeni z zoledronsko kislino, do konca študije ni bil dosežen in je bil značilno daljši kot s placebom (p=0,007).
In patients with mild to moderate renal impairment, reduced zoledronic acid doses are recommended (see section “Posology” above and section 4.4). 
Za bolnike z blago do zmerno okvaro ledvic so priporočljivi nižji odmerki zoledronske kisline (glejte poglavje "Odmerjanje" zgoraj in poglavje 4.4).
Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. 
Zoledronska kislina spada v skupino difosfonatov in deluje predvsem na kost.
Adults and older people 
Zdravljenje TIH Odrasli in starejši bolniki
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10% of peak after 4 hours and < 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28. 
dosegla vrh ob koncu infundiranja, nato je sledilo hitro zmanjšanje na < 10% najvišje koncentracije po 4 urah in na < 1% najvišje koncentracije po 24 urah; sledilo je dolgotrajno obdobje zelo nizke koncentracije, ki pred drugo infuzijo zoledronske kisline 28. dan ni presegla 0,1% najvišje koncentracije.
For storage conditions of Zoledronic acid Actavis after dilution, see section 6.3. 
Za pogoje shranjevanja zdravila Zoledronska kislina Actavis po redčenju glejte poglavje 6.3.
Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed. 
Bolnike, ki so dobili večje odmerke od priporočenih (glejte poglavje 4.2), je treba natančno kontrolirati, ker so pri takšnih bolnikih opažali okvaro delovanja ledvic (vključno z ledvično odpovedjo) in nepravilnosti elektrolitov v serumu
Median time to relapse (re-increase of albumin-corrected serum calcium ≥ 2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid). 
Mediani časa do ponovitve (ponovno zvišanje za albumin korigiranega serumskega kalcija ≥ 2,9 mmol/l) je bil pri prejemnikih zoledronske kisline od 30 do 40 dni in pri prejemnikih 90 mg pamidronata 17 dni (vrednosti p 0,001 za 4 mg in 0,007 za 8 mg zoledronske kisline).
Zoledronic acid Actavis must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. 
Zdravilo Zoledronska kislina Actavis smejo predpisovati in dajati bolnikom samo zdravstveni delavci, ki imajo izkušnje z uporabo intravenskih difosfonatov.
Zoledronic acid Actavis is contraindicated in breast-feeding women (see section 4.3). 
Zdravilo Zoledronska kislina Actavis je pri doječih ženskah kontraindicirano (glejte poglavje 4.3).
Patients being treated with Zoledronic acid Actavis should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown. 
Bolniki, ki dobivajo zdravilo Zoledronska kislina Actavis, sočasno ne smejo dobivati takšnih zdravil ali kakšnega drugega difosfonata, kajti učinki kombinacije teh učinkovin niso znani.
Contents of the pack and other information What Zoledronic acid Actavis contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Zoledronska kislina Actavis
In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ≥ 400 micromol/l or ≥ 4.5 mg/dl for patients with TIH and ≥ 265 micromol/l or ≥ 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of Zoledronic acid Actavis is not recommended in patients with severe renal impairment. 
Glede na možni vpliv zoledronske kisline na delovanje ledvic ter na pomanjkanje kliničnih podatkov o varnosti pri bolnikih s hudo izhodiščno okvaro ledvic (v kliničnih preskušanjih opredeljeno kot serumski kreatinin ≥ 400 mikromolov/l ali ≥ 4,5 mg/dl pri bolnikih s TIH oziroma kot serumski kreatinin ≥ 265 mikromolov/l ali ≥ 3,0 mg/dl pri bolnikih z rakom in metastazami v kosteh) in glede na omejene farmakokinetične podatke pri bolnikih s hudo izhodiščno okvaro ledvic (očistek kreatinina
There are no adequate data on the use of zoledronic acid in pregnant women. 
O uporabi zoledronske kisline pri nosečnicah ni dovolj podatkov.
Prevention of skeletal related events in patients with advanced malignancies involving bone: When initiating treatment with Zoledronic acid Actavis in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. 
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti: Ob uvedbi zdravila Zoledronska kislina Actavis pri bolnikih z multiplim mielomom ali metastatskimi kostnimi lezijami zaradi parenhimskih tumorjev je treba določiti serumski kreatinin in očistek kreatinina (CLcr).
- Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite. 
- Prebavne reakcije, npr. slabost v želodcu in bruhanje, pa tudi izguba apetita.
What you need to know before you are given Zoledronic acid Actavis 
Kaj morate vedeti, preden boste dobili zdravilo Zoledronska kislina Actavis
These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. 
Nekateri bolniki imajo bolečine v stegnu ali dimljah, pogosto hkrati z znaki stresnega zloma na slikah, že več tednov ali mesecev pred nastankom popolnega zloma stegnenice.
Vomiting, nausea 
Bruhanje, navzea
- Low level of magnesium and potassium in the blood. 
- Nizka koncentracija magnezija in kalija v krvi.
Zoledronic acid, used as indicated in sections 4.1 and 4.2, has been associated with reports of renal dysfunction. 
Zoledronska kislina, uporabljena, kot je navedeno v poglavjih 4.1 in 4.2, je bila povezana s poročili o motenem delovanju ledvic.
This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially “sodium-free”. 
Zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar pomeni, da je praktično "brez natrija".
During post-marketing experience the following reactions have been reported (frequency rare): Atypical subtrochanteric and diaphyseal femoral fractures (bisphopsphonate class adverse reaction). 
Med postmarketinško uporabo so bili opisani naslednji (po pogostnosti redki) učinki: atipični subtrohanterni zlomi stegnenice in zlomi diafize stegnenice (neželen učinek difosfonatov kot skupine).
- Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. 
- Redko se lahko pojavi nenavaden zlom stegnenice, predvsem pri bolnikih, ki dolgotrajno prejemajo zdravljenje za osteoporozo.
10 x 5 ml vials 
10 x 5 ml viale
Placebo Zoledronic acid 
Placebo Zoledronska kislina
In clinical trials 69 patients who relapsed or were refractory to initial treatment (zoledronic acid 4 mg, 8 mg or pamidronate 90 mg) were retreated with 8 mg zoledronic acid. 
V kliničnih preskušanjih so 69 bolnikov s ponovitvijo ali odpornostjo proti uvodnemu zdravljenju (4 ali 8 mg zoledronske kisline ali 90 mg pamidronata) ponovno zdravili z 8 mg zoledronske kisline.
Hypomagnesaemia, hypokalaemia 
Hipomagneziemija, hipokaliemija
Only clear solution free from particles and discolouration should be used. 
Uporabiti se sme le bistro raztopino brez delcev in nespremenjene barve.
The primary endpoint of the study was the percent change from baseline in lumbar spine bone mineral density (BMD) after 12 months of treatment. 
Primarni opazovani dogodek študije je bila odstotna sprememba mineralne gostote kosti (MGK) v ledveni hrbtenici po 12 mesecih zdravljenja v primerjavi z izhodiščem.
- The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line. 
- Raztopino, ki vsebuje zoledronsko kislino, je treba dati kot samostojno 15-minutno intravensko infuzijo z ločenim infuzijskim sistemom.
Population analysis showed that for a patient with creatinine clearance of 20 ml/min (severe renal impairment), or 50 ml/min (moderate impairment), the corresponding predicted clearance of zoledronic acid would be 37% or 72%, respectively, of that of a patient showing creatinine clearance of 84 ml/min. 
Populacijska analiza je pokazala, da bi bil pri bolniku z očistkom kreatinina 20 ml/min (huda okvara ledvic) ustrezni predvideni očistek 37% tistega pri bolniku z očistkom kreatinina 84 ml/min, pri bolniku z očistkom 50 ml/min (zmerna okvara) pa 72% tistega pri bolniku z očistkom 84 ml/min.
This resulted in exaggerated pharmacological effects considered to be related to the compound's inhibition of skeletal calcium metabolisation, resulting in periparturient hypocalcaemia, a bisphosphonate class effect, dystocia and early termination of the study. 
Prišlo je do poudarjenega farmakološkega delovanja, domnevno zaradi zaviranja presnove kalcija v kosteh; to je povzročilo peripartalno hipokalciemijo, kar je učinek difosfonatov kot skupine, distocijo in predčasno prekinitev študije.
In patients who show evidence of renal deterioration during treatment, Zoledronic acid Actavis should be withheld. 
Bolnikom, ki se jim med zdravljenjem poslabša delovanje ledvic, je treba zdravilo Zoledronska kislina Actavis ukiniti.
Over the first 24 hours, 39 ± 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. 
V prvih 24 urah se izloči v urinu 39 ± 16%
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Neželeni učinki so razvrščeni po oznakah pogostnosti, najpogostejši najprej, upoštevaje naslednji dogovor: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki
Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone. 
Če se vam pojavijo bolečine, šibkost ali nelagodje v stegnu, kolku ali dimljah, se morate posvetovati s svojim zdravnikom, kajti to so lahko zgodnji znaki možnega zloma stegnenice.
Zoledronic acid was well tolerated when administered subcutaneously to rats and intravenously to dogs at doses up to 0.02 mg/kg daily for 4 weeks. 
Podgane so dobro prenašale subkutano dano zoledronsko kislino, psi pa intravensko dano v odmerkih do 0,02 mg/kg na dan 4 tedne dolgo.
Caution is advised when zoledronic acid is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5). 
Pri dajanju zdravila Zoledronska kislina Actavis skupaj z zdravili, za katera je znano, da povzročajo hipokalciemijo, je potrebna previdnost, saj lahko delujejo sinergistično in povzročijo hudo hipokalciemijo (glejte poglavje 4.5).
All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Zoledronic acid Actavis. 
Vsem bolnikom je treba naročiti, naj v času zdravljenja z zdravilom Zoledronska kislina Actavis skrbijo za dobro ustno higieno in redno hodijo na preglede k zobozdravniku, v primeru simptomov v ustni votlini, kot so majavost zob, bolečine, otekline ali neceljenje ran ali vnetje, pa naj takoj obvestijo zdravnika.
Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found. 
Pri kuncih sicer niso ugotovili teratogenosti ali fetotoksičnosti, ugotovili pa so toksičnost za samice-matere.
You should not be given Zoledronic acid Actavis if you are pregnant. 
Zdravila Zoledronska kislina Actavis ne smete dobiti, če ste noseči.
You should not be given Zoledronic acid Actavis: 
Zdravila Zoledronska kislina Actavis ne smete dobiti:
Hypersensitivity reaction 
Preobčutljivostna reakcija
How to store Zoledronic acid Actavis Contents of the pack and other information 
Shranjevanje zdravila Zoledronska kislina Actavis Vsebina pakiranja in dodatne informacije
What Zoledronic acid Actavis is and what it is used for 
Kaj je zdravilo Zoledronska kislina Actavis in za kaj ga uporabljamo
It is especially important that you tell your doctor if you are also taking: - Aminoglycosides (medicines used to treat severe infections), calcitonin (a type of medicine used to treat post-menopausal osteoporosis and hypercalcaemia), loop diuretics (a type of medicine to treat high blood pressure or oedema) or other calcium-lowering medicines, since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low. 
- aminoglikozide (zdravila za zdravljenje hudih okužb), kalcitonin (vrsta zdravila, ki ga uporabljamo za zdravljenje pri postmenopavzalni osteoporozi in hiperkalciemiji), diuretike Henlejeve zanke (vrsta zdravila za zdravljenje visokega krvnega tlaka ali otekanja) ali druga zdravila, ki znižujejo koncentracijo kalcija, kajti kombinacija aminoglikozidov in difosfonatov lahko preveč zniža koncentracijo kalcija v krvi.
An extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly zoledronic acid over the 12-month extension treatment period in children who had completed one year of treatment with either zoledronic acid or pamidronate in the core study. 
Namenjeno je bilo preučitvi dolgoročne splošne in ledvične varnosti med uporabo zoledronske kisline enkrat ali dvakrat na leto v 12-mesečnem podaljšanju.
Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid and other bisphosphonates as well as use of other nephrotoxic medicinal products. 
Med dejavniki, ki lahko povečajo možnost za poslabšanje delovanja ledvic, so dehidracija, že obstoječa ledvična okvara, več ciklov zdravljenja z zoledronsko kislino ali drugimi difosfonati, pa tudi uporaba drugih nefrotoksičnih zdravil.
Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo. 
Analiza multiplih dogodkov je pokazala, da je 4 mg zoledronske kisline v primerjavi s placebom zmanjšalo tveganje za SRE za 41% (razmerje tveganj=0,59, p=0,019).
- To prepare an infusion solution containing 4 mg Zoledronic acid Actavis, further dilute the Zoledronic acid Actavis concentrate (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution. 
- Za pripravo raztopine za infundiranje, ki vsebuje 4 mg zdravila Zoledronska kislina Actavis, koncentrat zdravila Zoledronska kislina Actavis (5,0 ml) dodatno redčite s 100 ml raztopine za infundiranje, ki ne vsebuje kalcija in drugih dvovalentnih kationov.
Table 4: Efficacy results (breast cancer and multiple myeloma patients) 
Preglednica 4: Rezultati učinkovitosti (pri raku dojke in multiplem mielomu)
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid. 
Farmakokinetičnih podatkov o zoledronski kislini pri bolnikih s hiperkalciemijo ali z insuficienco jeter ni. Zoledronska kislina in vitro ne zavira človeških encimov P450, ne kaže biotransformacije, v študijah na živalih pa se je v blatu pojavilo < 3% uporabljenega; to kaže, da delovanje jeter v farmakokinetiki zoledronske kisline nima pomembne vloge.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2) . 
Predpisovanje in izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Bone pain, myalgia, arthralgia, generalised pain 
Kostne bolečine, mialgija, artralgija, generalizirana bolečina
The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 ± 33% of the creatinine clearance, which showed a mean of 84 ± 29 ml/min (range 22 to 143 ml/min) in the 64 cancer patients studied. 
Ledvični očistek zoledronske kisline je koreliral z očistkom kreatinina; ledvični očistek predstavlja 75± 33% očistka kreatinina, ki je bil pri 64 preučevanih bolnikih z rakom v povprečju 84 ± 29 ml/min
Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended. 
Med dejavniki, ki lahko povečajo možnost poslabšanja delovanja ledvic, so dehidracija, predhodna okvara ledvic, večkratni ciklusi zdravljenja z zoledronsko kislino ali drugimi difosfonati, pa tudi sočasna uporaba nefrotoksičnih zdravil in čas infundiranja, krajši od priporočenega.
Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid (see section 4.4). 
Poslabšanje delovanja ledvic, napredovanje v ledvično odpoved in dializo so bili zabeleženi pri bolnikih po začetnem ali enkratnem odmerku 4 mg zoledronske kisline (glejte poglavje 4.4).
- Skin reactions (redness and swelling) at the infusion site, rash, itching. 
- Kožne reakcije (pordelost in oteklost) na mestu infundiranja, izpuščaj, srbenje.
Zoledronic acid 4 mg 
Zoledronska kislina 4 mg
Dyspnoea, cough, bronchoconstriction Interstitial lung disease 
Dispneja, kašelj, bronhokonstrikcija
- Severe bone, joint and/or muscle pain, occasionally incapacitating. 
- Hude bolečine v kosteh, sklepih in/ali mišicah, ki bolnika v nekaterih primerih onemogočijo.
Hypocalcaemia has been reported in patients treated with zoledronic acid. 
Hipokalciemija Pri bolnikih, ki so bili zdravljeni z zoledronsko kislino, so poročali o hipokalciemiji.
- Shelf life after dilution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C and at 25°C after dilution in 100 ml 0.9% w/v sodium chloride solution or 100 ml 5% w/v glucose. 
- Rok trajanja po redčenju: Kemična in fizikalna stabilnost sta med uporabo dokazani 24 ur pri temperaturi od 2°C - 8°C in pri temperaturi 25°C po redčenju s 100 ml 0,9% m/v raztopine natrijevega klorida ali 100 ml 5% m/v glukoze.
- Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. 
- V primeru bolečine v ušesu, izcedka iz ušesa in/ali okužbe ušesa se posvetujte s svojim zdravnikom.
To avoid potential incompatibilities, Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion is to be diluted with 0.9% w/v sodium chloride solution or 5% w/v glucose solution. 
Da bi se izognili potencialnim inkompatibilnostim, je treba zdravilo Zoledronska kislina Actavis 4 mg/5 ml koncentrat za raztopino za infundiranje redčiti z 0,9% m/v raztopino natrijevega klorida ali 5% m/v raztopino glukoze.
Placebo Zoledronic acid 4 mg 
Placebo Zoledronska kislina 4 mg
- High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhoea, constipation, 
- Visok krvni tlak, kratka sapa, omotica, tesnoba, motnje spanja, motnje okušanja, tresenje,
Prior to administration, 5 ml concentrate from one vial or the volume of the concentrate withdrawn as required must be further diluted with 100 ml of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution). 
Pred dajanjem zdravila je treba 5 ml koncentrata iz ene viale ali potrebno izvlečeno količino koncentrata dodatno redčiti s 100 ml raztopine za infundiranje brez kalcija (0,9% m/v raztopine natrijevega klorida ali 5% m/v raztopine glukoze).
Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. 
Med zdravljenjem z difosfonati so bili opisani atipični subtrohanterni in diafizni zlomi stegnenice, predvsem pri bolnikih, ki so prejemali dolgotrajno zdravljenje za osteoporozo.
The following risk factors should be considered when evaluating an individual's risk of developing ONJ: - Potency of the bisphosphonate (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bisphosphonate. 
- Potentnost difosfonatov (večje tveganje pri visoko potentnih učinkovinah), pot uporabe (večje tveganje pri parenteralni uporabi) in kumulativni odmerek difosfonata.
In an in vitro study, zoledronic acid showed low affinity for the cellular components of human blood, with a mean blood to plasma concentration ratio of 0.59 in a concentration range of 30 ng/ml to 5000 ng/ml. 
V študiji in vitro je imela zoledronska kislina nizko afiniteto za celične sestavine humane krvi, pri čemer je znašala povprečna vrednost razmerja med koncentracijo v krvi in koncentracijo v plazmi 0,59
Many of these patients were also receiving chemotherapy and corticosteroids and had signs of local infection including osteomyelitis. 
Številni od teh bolnikov so prejemali tudi kemoterapijo in kortikosteroide in imeli znake lokalne okužbe, vključno z osteomielitisom.Večina poročil se nanaša na bolnike z rakom po ekstrakciji zoba ali kakšnem drugem dentalnem kirurškem posegu.
- The active substance is zoledronic acid. 
- Zdravilna učinkovina je zoledronska kislina.
In the clinical studies, patients with serum creatinine > 400 micromol/l or > 4.5 mg/dl were excluded. 
V klinične študije niso vključevali bolnikov s serumskim kreatininom > 400 mikromolov/l ali > 4,5 mg/dl.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient - skeletal morbidity rate. 
Zoledronska kislina v odmerku 4 mg je značilno zmanjšala delež bolnikov, ki se jim je pojavil vsaj en z okostjem povezan dogodek (SRE), podaljšala je mediani čas do prvega SRE za > 5
The following properties have been demonstrated in preclinical studies: - In vivo: Inhibition of osteoclastic bone resorption, which alters the bone marrow microenvironment, making it less conducive to tumour cell growth, anti-angiogenic activity and anti-pain activity. 
- In vivo: Zavrtje osteoklastne resorpcije kosti, ki spremeni mikrookolje kostnega mozga, tako da postane manj primerno za rast tumorskih celic, antiangiogeno in protibolečinsko aktivnost.
Patients treated with Zoledronic acid Actavis should be given the package leaflet and the patient reminder card. 
Bolnikom, ki prejemajo zdravilo Zoledronska kislina Actavis, je treba izročiti navodilo za uporabo in opozorilno kartico za bolnika.